"The European Commission as part of the global effort to fight poverty and to reach the Millennium Development Goals has invested millions of euros into seeking ways to control this major public health problem," an EU release said here today.
Normally associated with the developing countries where 219 million people are affected with the disease, as per WHO figures, the scientists now fear that with climate change it is possible that parts of Europe could also become affected by the disease.
With funding of EUR 3 million, France's Institute national de la sante et de la recherche medicale (INSERM) formed a unique consortium of EU and Indian partners for the project- 'MALSIG'.
The team generated various transgenic parasite strains to learn more about the proteins responsible for the disease. In addition new insights into DNA replication in gametocytes (a type of germ cell) have been gained through the study of cyclin-dependent protein kinase (CDKs), which regulate the cell cycle and effector molecules.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
